IBOV 166,608.52 ▼ 0.57% IPC MEX 70,819.80 ▲ 0.91% MERVAL 2,848,945 — — USD/BRL5.50▲ 0.83% USD/MXN18.75▲ 0.71% USD/CLP977.94▲ 1.18% USD/COP3,238▼ 0.39% USD/PEN3.44▼ 0.12% USD/ARS1,545▼ 0.19% USD/UYU40.22▲ 3.24% USD/PYG6,358▲ 9.88% USD/BOB11.92▲ 1.74% USD/DOP59.79▼ 1.17% USD/CRC449.63▲ 2.27% USD/GTQ7.64▲ 3.16% USD/HNL26.87▼ 0.09% USD/NIO36.62▲ 0.07% USD/VES892.65▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.94▲ 2.77% USD/TTD6.64▲ 1.14% EUR/BRL6.17▲ 0.51% BRENT 98.48 ▲ 4.08% WTI 90.67 ▲ 2.89% IRON ORE 161.91 — — COPPER 6.21 ▼ 2.98% GOLD 4,108 ▲ 0.87% SILVER 52.04 ▼ 0.15% SOY 1,190 ▼ 0.29% CORN 440.75 ▼ 0.79% WHEAT 599.25 ▲ 0.13% COFFEE 277.40 ▼ 0.84% SUGAR 18.60 ▲ 0.70% ORANGE JUICE 136.15 ▲ 3.54% COTTON 78.45 ▲ 0.44% COCOA 5,290 ▼ 3.04% BEEF 214.48 ▼ 1.62% CATTLE 320.58 ▼ 3.45% LITHIUM 60.28 ▼ 2.59% PETR4 46.31 ▼ 1.72% VALE3 62.70 ▲ 0.56% ITUB4 40.15 ▲ 1.11% BBDC4 13.83 ▼ 1.64% ABEV3 15.45 ▲ 1.31% BBAS3 16.54 ▲ 0.30% B3SA3 14.32 ▲ 0.14% WEGE3 48.26 ▼ 3.58% PRIO3 62.18 ▲ 0.06% SUZB3 52.36 ▲ 0.02% RENT3 29.23 ▼ 0.78% AZZA3 14.22 ▲ 1.79% CSAN3 2.50 ▲ 4.60% RAIZ4 27.57 ▲ 1.73% PCAR3 2.35 ▲ 2.17% GMAT3 3.67 ▲ 3.97% PSSA3 43.70 ▼ 2.65% CVCB3 0.81 — 0.00% POSI3 3.14 ▼ 0.95% SLCE3 16.38 ▼ 1.33% NATU3 5.35 ▼ 1.29% BRKM5 3.01 ▼ 1.31% RANI3 8.55 ▼ 0.93% CSNA3 4.09 ▲ 0.25% IBOV 166,608.52 ▼ 0.57% IPC MEX 70,819.80 ▲ 0.91% MERVAL 2,848,945 — — USD/BRL 5.50 ▲ 0.75% USD/MXN 18.77 ▲ 0.79% USD/CLP 977.94 ▲ 1.18% USD/COP 3,244 ▼ 0.18% USD/PEN 3.44 ▼ 0.09% USD/ARS 1,545 ▼ 0.19% USD/UYU 40.22 ▲ 3.24% USD/PYG 6,358 ▲ 9.88% USD/BOB 11.92 ▲ 1.74% USD/DOP 59.96 ▼ 0.89% USD/CRC 449.63 ▲ 2.27% USD/GTQ 7.64 ▲ 3.16% USD/HNL 26.87 ▼ 0.09% USD/NIO 36.62 ▲ 0.07% USD/VES 892.65 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.94 ▲ 2.77% USD/TTD 6.64 ▲ 1.14% EUR/BRL 6.17 ▲ 0.41% BRENT 98.48 ▲ 4.08% WTI 90.67 ▲ 2.89% IRON ORE 161.91 — — COPPER 6.21 ▼ 2.98% GOLD 4,108 ▲ 0.87% SILVER 52.04 ▼ 0.15% SOY 1,190 ▼ 0.29% CORN 440.75 ▼ 0.79% WHEAT 599.25 ▲ 0.13% COFFEE 277.40 ▼ 0.84% SUGAR 18.60 ▲ 0.70% ORANGE JUICE 136.15 ▲ 3.54% COTTON 78.45 ▲ 0.44% COCOA 5,290 ▼ 3.04% BEEF 214.48 ▼ 1.62% CATTLE 320.58 ▼ 3.45% LITHIUM 60.28 ▼ 2.59% PETR4 46.31 ▼ 1.72% VALE3 62.70 ▲ 0.56% ITUB4 40.15 ▲ 1.11% BBDC4 13.83 ▼ 1.64% ABEV3 15.45 ▲ 1.31% BBAS3 16.54 ▲ 0.30% B3SA3 14.32 ▲ 0.14% WEGE3 48.26 ▼ 3.58% PRIO3 62.18 ▲ 0.06% SUZB3 52.36 ▲ 0.02% RENT3 29.23 ▼ 0.78% AZZA3 14.22 ▲ 1.79% CSAN3 2.50 ▲ 4.60% RAIZ4 27.57 ▲ 1.73% PCAR3 2.35 ▲ 2.17% GMAT3 3.67 ▲ 3.97% PSSA3 43.70 ▼ 2.65% CVCB3 0.81 — 0.00% POSI3 3.14 ▼ 0.95% SLCE3 16.38 ▼ 1.33% NATU3 5.35 ▼ 1.29% BRKM5 3.01 ▼ 1.31% RANI3 8.55 ▼ 0.93% CSNA3 4.09 ▲ 0.25%
since 2009
Thursday, November 5, 2026

Covid-19 Brazil

ANVISA authorizes trials of another two vaccines against Covid-19 in Brazil

By · July 14, 2021 · 2 min read

RIO DE JANEIRO, BRAZIL – The Brazilian health regulatory agency ANVISA on Wednesday (14) announced that it granted authorization for clinical trials in Brazil of two potential vaccines against Covid-19, one developed by the Chinese Academy of Medical Sciences’ Institute of Medical Biology and the other by AstraZeneca, a new version of the manufacturer’s immunizer currently administered in Brazil.

According to the health regulator’s note, the potential immunizer developed in China uses inactivated vaccine technology and trials will cover Phase 3 – to assess the vaccine’s efficacy, safety and immunogenicity. The immunizer will be administered in two doses at a 14-day interval.

1
Brazil’s health regulator has authorized clinical trials of two potential vaccines against Covid-19.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

In addition to Brazil, trials will be conducted in China and in other countries with 34,020 volunteers. There will be 7,992 volunteers in Brazil in the states of Goiás, Rio de Janeiro, Santa Catarina, and São Paulo.

The new version of AstraZeneca’s vaccine uses recombinant adenovirus vector technology, the same as its immunizer produced in partnership with Oxford University and currently used in Brazil.

The potential new vaccine is a modified version of the existing immunizer, designed to provide immunity to the coronavirus variant that emerged in South Africa, ANVISA said.

Phase 2/3 trials to determine the vaccine candidate’s safety and immunogenicity will be administered in a single dose to people who have already received two doses of AstraZeneca’s current vaccine or another immunizer using messenger RNA technology.

It will also be tested as a two-dose immunizer on people who have not yet been vaccinated and as a second dose for those who have been administered a first dose of the current vaccine.

This study will be conducted with 2,475 volunteers in Brazil, the United Kingdom, South Africa, and Poland. In Brazil, it will include 800 volunteers in the states of Bahia, Federal District, Paraná, Rio Grande do Norte, Rio Grande do Sul, and São Paulo.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.